Kornimate/medical-research-clean huggingface dataset:
the effect of a planning prompt on seasonal influenza vaccination rates

Conditions: Seasonal Influenza

Summary: the investigators conducted a 3-arm randomized controlled trial to test whether a low-cost planning intervention could increase influence vaccination rates.

seasonal influenza causes 20,000 hospitalizations and 36,000 deaths in the u.s. each year. past psychology research has demonstrated that prompting people to form an implementation plan of the form, "when situation x arises, i will implement response y," increases attainment of desired goals because the desired behavior is linked to a concrete future moment. this type of planning prompt is a "nudge" in the direction of desired behavior that can be implemented at minimal expense and does not restrict individual autonomy. we conducted a 3-arm randomized controlled trial to test whether a low-cost planning intervention could increase influence vaccination rates. we show that planning prompts can be successfully applied to improve health behaviors.

Eligibility criteria:
inclusion criteria: * vaccine indications according to fall 2009 cdc criteria (age \>= 50 or chronic disease * employee at partner corporation that implemented the study exclusion criteria: * none

Keywords: seasonal influenza behavioral economics implementation intentions planning prompt nudge
pharmaco-neuroimaging studies of approach/avoidance behaviors and post-mortem studies: pharmacological manipulation

Conditions: Depressive Disorder, Major; Anxiety Disorder

Summary: the study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (mdd) and anxiety disorders. more specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin fq peptide and the nociceptin receptor (nopr).


Eligibility criteria:
inclusion criteria for mdd/anxiety disorder group: * dsm-5 diagnostic criteria for mdd, generalized anxiety disorder, social phobia, panic disorder, post traumatic stress (diagnosed using the scid-5) * written informed consent * for mdd subjects, a baseline hamilton depression rating scale score \> 16 (17-item version) * right-handed * has a smartphone (iphone or android) (needed for ecological momentary assessment) * absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine, 6 months for neuroleptics, 2 weeks for benzodiazepines, 2 weeks for any other antidepressants) inclusion criteria for healthy controls: * absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by subject history and a structured clinical interview (diagnosed using the scid-5) * written informed consent * right-handed * absence of any medications for at least 3 weeks * has a smartphone (iphone or android) (needed for ecological momentary assessment) exclusion criteria for all participants: * subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician * pregnant women or women of childbearing potential who are not using a medically accepted means of contraception * serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease * history of seizure disorder * history or current diagnosis of any of the following dsm-iv psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, obsessive-compulsive disorder, patients with mood congruent or mood incongruent psychotic features, substance dependence, substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse; which will lead to exclusion) * history of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine) * history of use of dopaminergic drugs (including methylphenidate) * history or current diagnosis of dementia * patients with mood congruent or mood incongruent psychotic features * current use of other psychotropic drugs * clinical or laboratory evidence of hypothyroidism * patients with a lifetime history of electroconvulsive therapy * failure to meet standard magnetic resonance imaging safety requirements * abnormal ecg and lab results * history of seizure disorder or currently on anticonvulsants
bladder arfi (acoustic radiation force impulse) study

Conditions: Bladder Fibrosis

Summary: urinary bladder fibrosis (thickening and scarring) is fairly uncommon in children. traditionally, the presence of urinary bladder fibrosis has been confirmed directly with bladder biopsy or using urodynamic testing. in this study we will use ultrasound scanning and arfi (acoustic radiation force impulse) wave velocities to potentially identify any urinary bladder wall fibrosis.

urinary bladder fibrosis (thickening and scarring) is fairly uncommon in children. traditionally, the presence of urinary bladder fibrosis has been confirmed directly with bladder biopsy or using urodynamic testing. we will use ultrasound arfi (acoustic radiation force impulse)-derived shear wave velocities to potentially identify the presence of urinary bladder wall fibrosis. we hypothesize that shear wave velocities found within the bladder wall will increase with increasing evidence of fibrosis.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or younger 2. have an order for urodynamic testing from your doctor exclusion criteria: 1. adults 2. unwilling to sign consent form
azd9833 china pk study

Conditions: ER+, HER2-, Metastatic Breast Cancer

Summary: a phase 1 dose escalation and expansion study of azd9833 alone or in combination in chinese patients with er positive, her2 negative, metastatic breast cancer

this study is designed to investigate and characterize the safety, tolerability and pk of azd9833 monotherapy (part a, part b-cohort 1) or in combination with palbociclib (optional part b cohort 2) or everolimus (optional part b cohort 3) and to explore the preliminary anti-tumour activity in chinese patients

Eligibility criteria:
inclusion criteria: 1. any menopausal status: 1. pre-menopausal women must have commenced treatment with an lhrh agonist at least 4 weeks prior to the start of study intervention and must be willing to continue to receive lhrh agonist therapy for the duration of the study. 2. post-menopausal defined according to standard criteria in the protocol. 2. histological or cytological confirmation of adenocarcinoma of the breast. 3. documented positive er status and her2 negative status of primary or metastatic tumour tissue. 4. ecog performance status 0 to 1. 5. metastatic disease and radiological or objective evidence of progression on or after the last systemic therapy prior to the start of study intervention. 6. at least one lesion as per recist version 1.1 that can be accurately assessed at baseline and is suitable for repeated assessment by ct, mri, or plain x-ray or clinical examination. 7. recurrence or progression on at least one line of endocrine therapy in the metastatic disease setting. 8. for part a and part b cohort 1, patients should be eligible for serd monotherapy treatment. 9. for part b cohort 2, patients should be eligible for serd treatment and cdk4/6 inhibitors, and prior treatment with cdk4/6 inhibitors is not permitted. 10. for part b cohort 3, patients should be eligible for serd treatment and mtor inhibitors, and prior treatment with mtor inhibitors is not permitted. exclusion criteria: 1. previous treatment with azd9833. 2. presence of life-threatening metastatic visceral disease, uncontrolled cns metastatic disease or life-threatening extensive hepatic involvement. 3. any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or infection requiring intravenous antibiotic therapy, which makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol. 4. inadequate bone marrow reserve or organ function. 5. any clinically important and symptomatic heart disease. 6. any concurrent anti-cancer treatment. 7. refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of azd9833 (and palbociclib and everolimus). the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: breast cancer open-label phase 1 safety tolerability pharmacokinetics er positive her2 negative metastatic breast cancer
accuracy of arch analysis in mixed dentition using digital models versus plaster ones.

Conditions: Dental Malocclusion

Summary: accuracy of arch analysis in mixed dentition using digital study models versus the plaster models using tanaka and johnston prediction equation:

space analysis is traditionally performed by diagnostic measurements that have been obtained from plaster dental casts through measurements which might be influenced by subjective interpretation and bias when constructed. \*so another method of diagnostically measuring study models was introduced (digital software). this system creates digital images of dental casts with software. from the digitized models, various analyses and routine measurements could be done that might accelerate and solve many problems and difficulties associated with storage, retrieval, reproduction, communication, and breakage of conventional plaster casts. * taking an impressions for a mixed dentition aged children. * perform a measurements using tanaka and johnston equation for an arch analysis using a caliper and 3shape ortho-analyzer software. * casts will be scanned using the 3d scanner then by using the 3shape software measurements will be held according to tanaka and johnstopn prediction equation.

Eligibility criteria:
inclusion criteria: * aged range from 6-10. * patients medically free from any syndromes that could affect the normal eruption. * normal radiographical findings in teeth eruption. * erupted lower incisors. exclusion criteria: * extracted lower 1st permanent molar. * congenital missing of incisors. * badly decayed permanent incisors or 1st molar that could compromise the measurements. * any sensitivity to any of the impression materials.

Keywords: arch analysis, mixed dentition,tanaka & johnston
immune spatial features of guselkumab cutaneous response

Conditions: Psoriasis of Scalp

Summary: this study examines the effect of il-23 blockade with guselkumab on the immune cells of scalp psoriasis lesions.

this is a one-arm, open-label study to examine the effect of guselkumab . guselkumab is a fda-approved medication for the treatment of psoriasis. this study will examine how guselkumab affects immune cells within scalp psoriasis lesions. ten subjects with moderate to severe scalp psoriasis will be enrolled. biopsy samples will be collected and undergo molecular profiling to correlate profiles with guselkumab treatment response.

Eligibility criteria:
inclusion criteria: possess a pssi (psoriasis scalp severity index) of ≥12 exclusion criteria: 1. taking systemic immunosuppressives in the last 4 weeks 2. pregnancy 3. severe immunodeficiency (either from genetic or infectious causes). 4. tuberculosis or other active serious infection 5. active systemic malignancy. 6. breast-feeding 7. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. 8. males who are trying to conceive -
pet/mri in cns and extra-cns tumors of patients with neurofibromatosis-1 (nf1)

Conditions: Neurofibromatosis-1; Optic Glioma; Plexiform Neurofibroma

Summary: this prospective pilot study is designed to provide preliminary data on the use of fluorodeoxyglucose positron emission tomography-magnetic resonance imaging (fdg-pet-mri) in patients with neurofibromatosis-1 (nf1) associated optic glioma and plexiform neurofibroma (pn). subjects will undergo fdg-pet-mri scans in place of standard of care imaging at 0 and 12 months, unless more frequent imaging is clinically indicated. subjects and their family caregivers will also undergo serial interviews and complete questionnaires related to the psychosocial aspects of nf1.


Eligibility criteria:
inclusion criteria: * diagnosed with neurofibromatosis-1 with either optic glioma, due for imaging scan, or plexiform neurofibroma, due for imaging secondary to clinical signs or symptoms of progressive disease * ≥ 6 years of age * english-speaking * if female of child-bearing potential, negative urine pregnancy test performed within 7 days prior to each fdg-pet-mri * study-specific informed consent or assent obtained and signed exclusion criteria: * unable to undergo fdg-pet-mri without sedation * currently undergoing chemotherapy for progressing optic glioma * pregnant or lactating female * poorly controlled diabetes mellitus * presence of pacemaker, intracranial aneurysm clip, cochlear implant, metal halo device, epicardial pacemaker leads, or any other device that makes mri unsafe * serum creatinine \> 1.8 mg/dl or gfr \< 30 ml/min * unable to lie flat for \> 1 hour * body mass index (bmi) \> 35
leveraging ai-ecg technology for early notification and tracking of af development

Conditions: Atrial Fibrillation (AF); Premature Atrial Complexes; Atrial Arrhythmias; Artificial Intelligence (AI); Electrocardiogram

Summary: our study aimed to use an af-predict ai-ecg alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (af), atrial flutter (afl), or atrial arrhythmia with high af risk, including premature atrial complexes (pac) ≥ 500/24hr, burst pacs \> 20 beats, non-sustained af/afl.


Eligibility criteria:
inclusion criteria: * patients in the inpatient department or the outpatient department * patients need to have at least one electrocardiogram within one year exclusion criteria: * diagnosis of atrial fibrillation/atrial flutter * history of atrial fibrillation/atrial flutter catheter ablation * patients with cardiac implantable electronic devices * any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm * history of received rhythm control medications for atrial arrhythmia, including class i and class iii antiarrhythmic drugs * any reasons indicate for anti-coagulant agents, including vitamin k antagonist and non-vitamin k antagonist oral anticoagulant
improving outcome in schizophrenia through identification of genetic risk factors

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depression

Summary: the goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.


Eligibility criteria:
inclusion criteria: patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder. exclusion criteria: patients with dsm-iv diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.
dornase alfa and urokinase for kids with pleural empyema

Conditions: Pleural Empyema

Summary: the purpose of this study is to determine whether intrapleural treatment with dornase alfa plus urokinase improves clinical outcome compared to urokinase alone in children with complicated parapneumonic effusions


Eligibility criteria:
inclusion criteria: * age \> 1 year and \< 16 years * respiratory infection (pneumonia or lung abscess) * effusion occupying at least 1/3 of hemithorax on chest x-ray * complicated effusion (presence of at least one of the following): * hyperechoic pleural fluid on chest us scan * loculated collection on chest us or ct scan * purulent pleural fluid * positive culture or gram stain on pleural fluid exclusion criteria: * non parapneumonic effusion * immunodeficiency * neurological impairment * suspected or proven allergy to urokinase or dornase alfa * suspected or documented bronchopleural fistula * impaired coagulation (inr\>2), haemorrhage, high risk for bleeding * thoracic surgical procedure (e.g. thoracoscopy, mini-thoracotomy) already performed * chest drain inserted since 6 or more days

Keywords: pleural empyema pleural effusion dornase alfa urokinase children
comparison between colorectal stents and primary surgery in obstructive colonic cancer. a randomized, controlled study

Conditions: Colorectal Obstruction; Left Colonic Adenocarcinoma

Summary: to evaluate wether colorectal stenting carry a significant clinical advantage

randomized controlled comparison between stents and primary surgery in obstructive left colonic obstructive carcinoma outside palliative situations.

Eligibility criteria:
inclusion criteria: * obstructive stenosis due to left colorectal cancer exclusion criteria: * previous colorectal cancer * other colorectal location

Keywords: colorectal stents colonic obstruction colonic adenocarcinoma colorectal surgery
glucagon-like peptide-1 in type 1 diabetes

Conditions: Type1 Diabetes Mellitus

Summary: the hypotheses to be tested in this application is: glp-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in t1dm.

the naturally occurring hormone glp-1 when co-administered during hypoglycemia (low blood sugar) in non-diabetic individuals can reduce the deleterious effects of hypoglycemia on the vasculature. we have shown that iv infusion of glp-1 during a single moderate episode of hypoglycemia can preserve endothelial function and protect the vasculature from pro-coagulant and pro-inflammatory effects in healthy individuals. it is unknown whether glp-1 could protect the vasculature during episodes of repeated hypoglycemia and whether glp-1 would have protective effects in t1dm individuals.

Eligibility criteria:
inclusion criteria: * 40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr. * hba1c \< 11.0% * body mass index \< 40kg • m-2 * no clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc) exclusion criteria: * subjects unable to give voluntary informed consent * pregnancy * subjects on anticoagulant drugs, anemic or with known bleeding diatheses * subjects taking any of the following medications will be excluded: non-selective beta blockers, * sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants, * mood stabilizers, cns stimulants, opioids, hallucinogens * subjects unwillingness or inability to comply with approved contraception measures * subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents * clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, s-t segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old. * pneumonia * hepatic failure /jaundice * abnormal results following screening tests and physical examination that are clinically significant * acute cerebrovascular/ neurological deficit * fever greater than 38.0 c * screening laboratory tests exclusion criteria * hematocrit lower than 32 * wbc lower than 3 thou/ul or greater than 14 thou/ul * liver function tests: sgot and sgpt greater than twice upper limit of normal range (i.e. \> 80 u/l) * tbil \> 2 mg/dl * creatinine \> 1.6 mg/dl * alkaline phosphatase \> 150u/l * hepatic transaminase \> 2x normal
does the advice to eat a mediterranean diet with low carbohydrate intake, compared with a low-fat diet, reduce diabetes and cardiovascular disease?

Conditions: Ischemic Heart Disease

Summary: this is a multi-centre, open, randomised study in patients treated for ischemic heart disease in linköping, norrköping and jönköping hospitals. one thousand two hundred patients who are treated at the cardiac rehabilitation units will be consecutively recruited during three years. the patients will be randomised 1:1 to be given advice on a 1) mediterranean diet with an energy content (e%) from carbohydrates between 25-30% or to 2) a traditional low-fat diet with 45-60 e% from carbohydrates. all eligible patients will be asked if they want to participate and provided with written information about the study when they are discharged from the hospital after treatment for ischemic heart disease. the decision to participate or not will be given at the following outpatient treatment at the cardiac rehabilitation unit. when the signed informed consent to participate in the study has been provided, the patient will be randomised to advice of either of the two dietary regimes.

aim to compare advice on a mediterranean diet with an energy content (e%) from carbohydrates between 25-30 e% with a traditional low-fat diet with 45-60 e% from carbohydrates. primary outcome incidence of diabetes in non-diabetic patients or glycaemic control in patients with known diabetes. secondary outcome recurrence of cardiovascular disease, blood lipid levels, quality of life by questionnaires. study design and study population this is a multi-centre, open, randomised study in patients treated for ischemic heart disease in linköping, norrköping and jönköping hospitals. one thousand two hundred patients who are treated at the cardiac rehabilitation units will be consecutively recruited during three years. the patients will be randomised 1:1 to be given advice on a 1) mediterranean diet with an energy content (e%) from carbohydrates between 25-30% or to 2) a traditional low-fat diet with 45-60 e% from carbohydrates. all eligible patients will be asked if they want to participate and provided with written information about the study when they are discharged from the hospital after treatment for ischemic heart disease. the decision to participate or not will be given at the following outpatient treatment at the cardiac rehabilitation unit. when the signed informed consent to participate in the study has been provided, the patient will be randomised to advice of either of the two dietary regimes.

Eligibility criteria:
inclusion criteria: patients treated for ischemic heart disease who are followed up at the cardiac rehabilitation units exclusion criteria: inability to affect food choice. severe concomitant disease such as malignancy, renal failure, heart failure or psychiatric disease.

Keywords: cardiovascular disease, diet, diabetes